WASHINGTON — Eli Lilly would’ve had to pay Medicaid about $150 for each vial of insulin used in the program if it hadn’t dramatically cut the list prices for some of its older products this week.
The company was about to run into a Medicaid penalty for hiking the price of its drugs faster than the rate of inflation. Now that it plans to lower the list price of the insulin Humalog 70%, it won’t trigger that penalty. Lilly also is lowering the price of Lispro, a biosimilar of Humalog, to $25 a vial.
It’s an upside for Lilly that has been largely overlooked since the Indianapolis-based pharma giant announced the policy change Wednesday. Company executives said they lowered prices to make insulin more available to people with diabetes, especially those “who may have difficulty navigating a complex health care system that may keep them from getting affordable insulin.” President Biden, who tweeted about the “huge news” shortly after Lilly’s announcement, credited the drug pricing legislation Democrats passed last fall.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect